https://www.centerforbiosimilars.com/view/no-efficacy-loss-after-multiple-ustekinumab-biosimilar-switches-in-psoriasis2026-04-02T16:36:01.289Z2026-04-02T16:36:01.289Z https://www.centerforbiosimilars.com/view/fda-approves-teva-biosimilar-for-denosumab-in-osteoporosis2026-03-31T14:03:08.491Z2026-03-31T14:03:08.491Z https://www.centerforbiosimilars.com/view/bone-health-in-oncology-closing-gaps-reducing-costs-and-unlocking-biosimilar-value2026-03-30T17:26:51.398Z2026-03-30T17:26:51.398Z https://www.centerforbiosimilars.com/view/biosimilar-ct-p43-matches-ustekinumab-in-treating-moderate-to-severe-plaque-psoriasis2026-03-20T23:15:44.964Z2026-03-20T23:15:44.964Z https://www.centerforbiosimilars.com/view/golimumab-biosimilar-matches-reference-drug-in-year-long-ra-trial2026-03-19T15:15:59.475Z2026-03-19T15:15:59.475Z https://www.centerforbiosimilars.com/view/switching-to-biosimilar-etanercept-shows-no-impact-on-efficacy-safety-across-18-trials2026-03-16T17:00:29.430Z2026-03-16T17:00:29.430Z https://www.centerforbiosimilars.com/view/gaps-in-knowledge-persist-around-biosimilar-insulin-switching-review-finds2026-03-12T17:45:29.686Z2026-03-12T17:45:29.686Z https://www.centerforbiosimilars.com/view/global-biosimilar-market-sees-structural-shifts-regulatory-hurdles-and-pipeline-gains2026-03-10T19:37:56.680Z2026-03-10T19:37:56.680Z https://www.centerforbiosimilars.com/view/fda-issues-draft-guidance-aimed-at-cutting-expenses-for-biosimilar-pk-studies2026-03-09T20:30:05.787Z2026-03-09T20:30:05.787Z https://www.centerforbiosimilars.com/view/clinician-confidence-in-ophthalmology-biosimilars-remains-low-across-europe2026-03-06T19:38:40.779Z2026-03-06T19:38:40.779Z https://www.centerforbiosimilars.com/view/biosimilars-development-roundup-expanding-global-treatment-options-amidst-rising-us-legal-hurdles2026-03-05T20:37:12.918Z2026-03-05T20:37:12.918Z https://www.centerforbiosimilars.com/view/biosimilar-backed-triplet-regimen-shows-feasibility-in-heavily-pretreated-liver-cancer2026-02-27T14:00:00.000Z2026-02-27T14:00:00.000Z https://www.centerforbiosimilars.com/view/omalizumab-biosimilar-entry-linked-to-expanded-patient-access-reduced-spending2026-02-26T14:27:00.000Z2026-02-26T14:27:00.000Z https://www.centerforbiosimilars.com/view/postmenopausal-osteoporosis-clinical-burden-treatment-barriers-and-the-evolving-role-of-denosumab-biosimilars2026-02-25T15:44:02.715Z2026-02-25T15:44:02.715Z https://www.centerforbiosimilars.com/view/cardinal-health-biosimilar-report-56-billion-in-savings-and-the-road-to-market-sustainability2026-02-24T14:00:00.000Z2026-02-24T14:00:00.000Z https://www.centerforbiosimilars.com/view/biosimilar-trastuzumab-emtansine-shows-consistent-pfs-in-her2-positive-breast-cancer2026-02-20T14:52:09.858Z2026-02-20T14:52:09.858Z https://www.centerforbiosimilars.com/view/fda-approves-filkri-accord-biopharma-s-short-acting-filgrastim-biosimilar-for-neutropenia2026-02-18T19:25:00.000Z2026-02-18T19:25:00.000Z https://www.centerforbiosimilars.com/view/danish-registry-analysis-finds-consistent-safety-after-switching-to-infliximab-biosimilar-gp11112026-02-03T14:00:00.000Z2026-02-03T14:00:00.000Z https://www.centerforbiosimilars.com/view/q-a-with-dr-chelsee-jensen-fda-policy-shifts-biosimilar-development-hurdles-and-market-access-in-20262026-02-02T17:45:00.000Z2026-02-02T17:45:00.000Z https://www.centerforbiosimilars.com/view/early-evidence-supports-km118-as-a-biosimilar-to-reference-pertuzumab2026-01-28T22:00:20.603Z2026-01-28T22:00:20.603Z https://www.centerforbiosimilars.com/view/milestone-approvals-evolving-pbm-models-may-redefine-2026-biosimilar-landscape2026-01-27T16:32:46.215Z2026-01-27T16:32:46.215Z https://www.centerforbiosimilars.com/view/fda-draft-guidance-on-biosimilars-is-a-win-for-patients-now-congress-must-finish-the-job2026-01-26T22:07:22.746Z2026-01-26T22:07:22.746Z https://www.centerforbiosimilars.com/view/biosimilar-competition-linked-to-lower-out-of-pocket-costs-for-medicare-patients2026-01-21T19:54:04.524Z2026-01-21T19:54:04.524Z https://www.centerforbiosimilars.com/view/perceptions-still-play-a-central-role-in-biosimilar-insulin-switching2026-01-20T22:01:09.551Z2026-01-20T22:01:09.551Z https://www.centerforbiosimilars.com/view/trial-data-support-equivalence-of-denosumab-biosimilar-in-postmenopausal-osteoporosis2026-01-16T13:37:46.873Z2026-01-16T13:37:46.873Z https://www.centerforbiosimilars.com/view/what-australia-s-experience-reveals-about-biosimilar-adoption-and-pricing2026-01-15T19:07:39.894Z2026-01-15T19:07:39.894Z https://www.centerforbiosimilars.com/view/eye-on-pharma-global-approvals-launches-and-strategic-partnerships2026-01-12T19:25:24.670Z2026-01-12T19:25:24.670Z https://www.centerforbiosimilars.com/view/real-world-study-finds-stable-vision-after-switch-to-ranibizumab-biosimilar2026-01-07T17:26:26.510Z2026-01-07T17:26:26.510Z https://www.centerforbiosimilars.com/view/evidence-supports-safe-effective-switching-to-etanercept-biosimilars2026-01-06T19:33:57.196Z2026-01-06T19:33:57.196Z https://www.centerforbiosimilars.com/view/fda-approves-amneal-denosumab-biosimilars-capping-year-of-market-expansion2026-01-06T12:00:00.000Z2026-01-06T12:00:00.000Z https://www.centerforbiosimilars.com/view/evidence-gaps-continue-to-shape-biosimilar-adoption-in-pediatric-care2026-01-05T07:00:00.000-05:002026-01-05T07:00:00.000-05:00 https://www.centerforbiosimilars.com/view/biosimilar-market-momentum-eu-approvals-strategic-launches-and-major-us-partnerships2026-01-02T12:00:00.000Z2026-01-02T12:00:00.000Z https://www.centerforbiosimilars.com/view/top-5-most-read-biosimilar-news-of-20252025-12-31T12:00:00.000Z2025-12-31T12:00:00.000Z https://www.centerforbiosimilars.com/view/top-5-most-read-gastroenterology-articles-of-20252025-12-29T12:00:00.000Z2025-12-29T12:00:00.000Z https://www.centerforbiosimilars.com/view/top-5-most-read-ophthalmology-articles-of-20252025-12-26T12:00:00.000Z2025-12-26T12:00:00.000Z https://www.centerforbiosimilars.com/view/top-5-most-read-bone-health-articles-of-20252025-12-24T12:00:00.000Z2025-12-24T12:00:00.000Z https://www.centerforbiosimilars.com/view/biorationality-the-new-era-of-affordable-biosimilar-development2025-12-23T12:00:00.000Z2025-12-23T12:00:00.000Z https://www.centerforbiosimilars.com/view/top-5-most-read-policy-articles-of-20252025-12-22T12:00:00.000Z2025-12-22T12:00:00.000Z https://www.centerforbiosimilars.com/view/top-5-most-read-regulatory-articles-of-20252025-12-19T12:00:00.000Z2025-12-19T12:00:00.000Z https://www.centerforbiosimilars.com/view/first-natalizumab-biosimilar-tyruko-launches-expanding-access-in-multiple-sclerosis2025-12-18T14:30:00.928Z2025-12-18T14:30:00.928Z https://www.centerforbiosimilars.com/view/denosumab-golimumab-biosimilars-clear-major-regulatory-milestones-in-europe-as-us-hurdles-remain2025-12-16T21:19:55.505Z2025-12-16T21:19:55.505Z https://www.centerforbiosimilars.com/view/biorationality-fda-issues-new-guidance-on-promotional-communications-for-biosimilar-products2025-12-11T17:46:37.736Z2025-12-11T17:46:37.736Z https://www.centerforbiosimilars.com/view/medicare-modeling-shows-major-savings-with-biosimilar-bevacizumab-use2025-12-09T16:45:21.726Z2025-12-09T16:45:21.726Z https://www.centerforbiosimilars.com/view/biosimilar-ql1207-demonstrates-equivalent-efficacy-and-safety-in-dme2025-12-08T16:45:00.000Z2025-12-08T16:45:00.000Z https://www.centerforbiosimilars.com/view/swiss-analysis-shows-biosimilars-cut-costs-but-longer-interval-options-lead-savings2025-12-04T21:36:14.528Z2025-12-04T21:36:14.528Z https://www.centerforbiosimilars.com/view/biosimilars-news-roundup-approvals-surge-amid-policy-changes2025-12-02T16:42:54.660Z2025-12-02T16:42:54.660Z https://www.centerforbiosimilars.com/view/all-things-biosimilars-how-streamlined-ces-rules-could-shift-the-market2025-11-30T15:37:36.116Z2025-11-30T15:37:36.116Z https://www.centerforbiosimilars.com/view/biosimilar-interchangeability-and-substitution-in-the-us-what-comes-next-2025-11-27T12:00:00.000Z2025-11-27T12:00:00.000Z https://www.centerforbiosimilars.com/view/economic-analysis-supports-formulary-shift-to-biosimilar-denosumab2025-11-26T12:00:00.000Z2025-11-26T12:00:00.000Z https://www.centerforbiosimilars.com/view/patient-experiences-with-ct-p17-suggest-strong-satisfaction-and-ease-of-injection2025-11-25T20:21:50.958Z2025-11-25T20:21:50.958Z https://www.centerforbiosimilars.com/view/real-world-data-highlight-adalimumab-biosimilar-options-for-hidradenitis-suppurativa2025-11-21T18:36:29.276Z2025-11-21T18:36:29.276Z https://www.centerforbiosimilars.com/view/fda-approves-poherdy-first-interchangeable-biosimilar-to-perjeta2025-11-18T18:08:21.823Z2025-11-18T18:08:21.823Z https://www.centerforbiosimilars.com/view/webinar-aligning-biosimilar-access-policy-with-global-health-priorities2025-11-14T21:43:36.886Z2025-11-14T21:43:36.886Z https://www.centerforbiosimilars.com/view/fda-quietly-approves-denosumab-biosimilars-issues-interchangeability-for-others2025-11-13T22:14:14.035Z2025-11-13T22:14:14.035Z https://www.centerforbiosimilars.com/view/global-data-show-variety-in-adalimumab-biosimilar-design-patient-support-systems2025-11-07T12:00:00.000Z2025-11-07T12:00:00.000Z https://www.centerforbiosimilars.com/view/biosimilar-monthly-roundup-october-20252025-11-06T21:42:46.952Z2025-11-06T21:42:46.952Z https://www.centerforbiosimilars.com/view/data-confirm-biosimilar-bmab-1200-performance-in-psoriasis-through-1-year2025-11-06T12:00:00.000Z2025-11-06T12:00:00.000Z https://www.centerforbiosimilars.com/view/uk-experts-publish-guidance-on-jc-virus-testing-for-natalizumab-biosimilar-tyruko2025-11-05T12:00:00.000Z2025-11-05T12:00:00.000Z https://www.centerforbiosimilars.com/view/global-regulatory-gridlock-hinders-biosimilar-savings-expert-panel-warns2025-11-04T12:00:00.000Z2025-11-04T12:00:00.000Z https://www.centerforbiosimilars.com/view/a-closer-look-at-new-fda-guidance-removing-barriers-to-biosimilar-development2025-10-30T14:00:00.000Z2025-10-30T14:00:00.000Z https://www.centerforbiosimilars.com/view/biorationality-the-fda-sets-sights-on-removing-clinical-efficacy-studies-for-biosimilars2025-10-29T17:10:25.874Z2025-10-29T17:10:25.874Z https://www.centerforbiosimilars.com/view/biosimilars-improve-health-system-resilience-in-latin-american-caribbean-nations2025-10-28T18:32:47.291Z2025-10-28T18:32:47.291Z https://www.centerforbiosimilars.com/view/comparable-insulin-glargine-biosimilar-could-help-relieve-diabetes-costs2025-10-27T20:40:42.923Z2025-10-27T20:40:42.923Z https://www.centerforbiosimilars.com/view/data-confirm-biosimilar-ranibizumab-non-inferiority-as-myopic-cnvm-treatment2025-10-24T17:30:41.547Z2025-10-24T17:30:41.547Z https://www.centerforbiosimilars.com/view/later-line-therapies-drive-biosimilar-prescriptions-in-turkish-rheumatology-practices2025-10-15T16:57:49.984Z2025-10-15T16:57:49.984Z https://www.centerforbiosimilars.com/view/biosimilar-bevacizumab-matches-avastin-in-treating-retinopathy-of-prematurity2025-10-14T20:36:07.297Z2025-10-14T20:36:07.297Z https://www.centerforbiosimilars.com/view/fda-approves-celltrion-aflibercept-biosimilar-eydenzelt2025-10-13T15:48:47.749Z2025-10-13T15:48:47.749Z https://www.centerforbiosimilars.com/view/real-world-stability-confirmed-for-ranibizumab-biosimilar-ximluci-in-prefilled-syringes2025-10-09T20:53:56.683Z2025-10-09T20:53:56.683Z https://www.centerforbiosimilars.com/view/review-identifies-gaps-in-evidence-on-biosimilar-dmard-use-during-pregnancy2025-10-09T17:53:52.050Z2025-10-09T17:53:52.050Z https://www.centerforbiosimilars.com/view/global-biosimilars-market-sees-gains-in-access-and-pipeline-expansion2025-10-07T18:18:03.330Z2025-10-07T18:18:03.330Z https://www.centerforbiosimilars.com/view/proposed-aflibercept-biosimilar-shows-comparable-safety-efficacy-in-phase-3-amd-trial2025-10-02T11:00:00.000Z2025-10-02T11:00:00.000Z https://www.centerforbiosimilars.com/view/biosimilars-news-roundup-september-20252025-10-01T11:01:00.000Z2025-10-01T11:01:00.000Z https://www.centerforbiosimilars.com/view/analysis-highlights-fiscal-access-benefits-of-omalizumab-biosimilars-in-europe2025-09-30T11:13:00.000Z2025-09-30T11:13:00.000Z https://www.centerforbiosimilars.com/view/biosimilar-tocilizumab-shows-cost-effectiveness-advantage-in-spanish-ra-population2025-09-29T11:00:00.000Z2025-09-29T11:00:00.000Z https://www.centerforbiosimilars.com/view/the-top-5-biosimilar-articles-for-the-week-of-september-222025-09-26T11:00:00.000Z2025-09-26T11:00:00.000Z https://www.centerforbiosimilars.com/view/eye-on-pharma-europe-and-mena-region-see-expanding-biosimilar-pipelines2025-09-25T11:00:00.000Z2025-09-25T11:00:00.000Z https://www.centerforbiosimilars.com/view/biosimilars-drive-savings-and-access-yet-looming-development-gap-threatens-future2025-09-23T13:30:00.000Z2025-09-23T13:30:00.000Z https://www.centerforbiosimilars.com/view/stable-treatment-persistence-in-ra-after-etanercept-biosimilar-introduction-in-australia2025-09-23T11:00:00.000Z2025-09-23T11:00:00.000Z https://www.centerforbiosimilars.com/view/global-aflibercept-biosimilar-progress-signals-rising-access-for-retinal-disease-care2025-09-22T11:00:00.000Z2025-09-22T11:00:00.000Z https://www.centerforbiosimilars.com/view/ec-approves-new-biosimilars-for-bone-and-eye-conditions2025-09-19T16:54:17.669Z2025-09-19T16:54:17.669Z https://www.centerforbiosimilars.com/view/fda-approves-biocon-biologics-denosumab-biosimilars-bosaya-and-aukelso2025-09-18T15:49:02.370Z2025-09-18T15:49:02.370Z https://www.centerforbiosimilars.com/view/biorationality-no-more-clinical-efficacy-testing-for-biosimilars-going-from-biosimilars-to-biogenerics2025-09-16T21:30:18.484Z2025-09-16T21:30:18.484Z https://www.centerforbiosimilars.com/view/real-world-evidence-supports-biosimilar-hlx02-in-metastatic-breast-cancer2025-09-11T20:14:02.494Z2025-09-11T20:14:02.494Z https://www.centerforbiosimilars.com/view/australian-study-reveals-significant-cost-savings-and-market-impact-from-biosimilars2025-09-10T11:00:00.000Z2025-09-10T11:00:00.000Z https://www.centerforbiosimilars.com/view/switch-to-biosimilar-adalimumab-found-safe-and-cost-saving-for-patients-with-ibd2025-09-09T11:00:00.000Z2025-09-09T11:00:00.000Z https://www.centerforbiosimilars.com/view/sysa1902-biosimilar-proves-equivalent-to-reference-ustekinumab-in-plaque-psoriasis2025-09-08T11:00:00.000Z2025-09-08T11:00:00.000Z https://www.centerforbiosimilars.com/view/the-top-5-biosimilar-articles-for-the-week-of-september-12025-09-05T16:15:19.503Z2025-09-05T16:15:19.503Z https://www.centerforbiosimilars.com/view/japanese-trial-supports-widespread-use-safety-of-infliximab-biosimilar-use2025-09-04T19:59:36.501Z2025-09-04T19:59:36.501Z https://www.centerforbiosimilars.com/view/patients-with-namd-maintain-vision-on-aflibercept-biosimilar-abp-9382025-09-03T13:30:00.000Z2025-09-03T13:30:00.000Z https://www.centerforbiosimilars.com/view/biosimilars-news-roundup-august-20252025-09-02T20:05:34.833Z2025-09-02T20:05:34.833Z https://www.centerforbiosimilars.com/view/fda-greenlights-fifth-pair-of-denosumab-biosimilars-bildyos-and-bilprevda2025-09-02T14:15:00.000Z2025-09-02T14:15:00.000Z https://www.centerforbiosimilars.com/view/the-top-5-biosimilar-articles-for-the-week-of-august-252025-08-29T11:00:00.000Z2025-08-29T11:00:00.000Z https://www.centerforbiosimilars.com/view/alvotech-reports-record-breaking-first-half-of-2025-amid-strong-biosimilar-sales2025-08-27T11:00:00.000Z2025-08-27T11:00:00.000Z https://www.centerforbiosimilars.com/view/canadian-rwe-show-comparable-outcomes-between-etanercept-biosimilars-originator2025-08-26T14:37:59.317Z2025-08-26T14:37:59.317Z https://www.centerforbiosimilars.com/view/biosimilar-romiplostim-shows-equivalent-efficacy-to-reference-product-for-chronic-itp2025-08-25T17:25:00.000Z2025-08-25T17:25:00.000Z https://www.centerforbiosimilars.com/view/the-top-5-biosimilar-articles-for-the-week-of-august-182025-08-22T16:00:00.000Z2025-08-22T16:00:00.000Z https://www.centerforbiosimilars.com/view/ten-years-of-data-support-safety-of-biosimilar-filgrastim-for-donor-mobilization2025-08-22T13:30:00.000Z2025-08-22T13:30:00.000Z https://www.centerforbiosimilars.com/view/litigation-launch-and-lower-costs-3-big-moves-in-the-us-biosimilar-space2025-08-19T19:42:37.786Z2025-08-19T19:42:37.786Z https://www.centerforbiosimilars.com/view/the-top-5-biosimilar-articles-for-the-week-of-august-112025-08-15T12:00:00.000Z2025-08-15T12:00:00.000Z https://www.centerforbiosimilars.com/view/denosumab-biosimilar-ly01011-shows-equivalence-to-reference-product-for-bone-metastases2025-08-14T13:00:00.000Z2025-08-14T13:00:00.000Z